TrumpRx Faces 6-Month Access Test as AMCP Warns Pharmacy Gaps Can Block Savings

Q: Why might a heavily advertised cheap prescription still leave you paying more out-of-pocket than a standard insurance copay?

A heavily advertised “cheap” prescription can still cost you more because the promoted price is usually a cash price, while your insurance copay may be lower for that same drug. That is the central tradeoff Adam Colborn highlighted: a lower posted price does not automatically mean the lowest real cost at the counter. Discount platforms such as TrumpRx, GoodRx, or similar tools typically cannot be combined with insurance in the same transaction. The pharmacist runs either your insurance or the discount cash price, and sometimes the insurance copay wins. This is especially true for insured patients whose plans place a generic or preferred brand on a low-cost tier. In those cases, a standard copay may be only a few dollars, while the advertised discount price is higher. Reporting on TrumpRx also noted it is often most useful for cash-paying patients or for drugs not well covered by insurance, not for every insured person. There is another hidden cost: if you choose the cash discount instead of insurance, that spending often does not count toward your deductible or annual out-of-pocket maximum, especially in Medicare Part D and many private plans. So even if the cash price looks competitive today, it can leave you worse off over the year. Colborn’s broader point is that affordability and access are different. A quoted bargain matters only if the pharmacy accepts it, the drug is available, and the final amount you pay is actually lower than your insurance option.

2 articles · Updated · pharmaceuticalcommerce.com · Aug 12

Six months after TrumpRx began touting lower drug prices, AMCP’s Adam Colborn said the platform’s real measure is whether patients can actually fill prescriptions through participating pharmacies.
Colborn argued affordability and access are not the same: a lower listed price does little if pharmacy participation gaps leave patients unable to use the offer at the counter.
He said AMCP member survey findings already showed skepticism that TrumpRx consistently delivers the lowest available price, calling the current savings narrative more messaging than hard data.
Colborn placed TrumpRx alongside price-comparison and discount models such as GoodRx, Amazon and Mark Cuban Cost Plus Drugs, framing access execution—not headline pricing—as the broader competitive test.